PBYI — Puma BioTech

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcom...

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Industry

PHARMACEUTICAL PREPARATIONS

Sector

Healthcare

Exchange

NASD

First trade date

2012-03-21

The interactive platform loads with JavaScript. Research tools are for informational purposes.